menu search

PFE / Pfizer Inc. (PFE) Q2 2023 Earnings Call Transcript

Pfizer Inc. (PFE) Q2 2023 Earnings Call Transcript
Pfizer Inc. (NYSE:PFE ) Q2 2023 Results Conference Call August 1, 2023 10:00 AM ET Company Participants Chris Stevo - SVP and Chief IR Officer Dr. Albert Bourla - Chairman and CEO Dave Denton - CFO Dr. Mikael Dolsten - Chief Scientific Officer and President, Pfizer R&D Angela Hwang - Chief Commercial Officer and President, Global Biopharmaceuticals Business Aamir Malik - Chief Business Innovation Officer Dr. Chris Boshoff - Chief Oncology R&D Officer Conference Call Participants Nicole Germino - Truist Securities Umer Raffat - Evercore Evan Seigerman - BMO Terence Flynn - Morgan Stanley Chris Shibutani - Goldman Sachs Louise Chen - Cantor Mohit Bansal - Wells Fargo Trung Huynh - Credit Suisse Colin Bristow - UBS Kerry Holford - Berenberg Geoff Meacham - Bank of America Tim Anderson - Wolfe Research Carter Gould - Barclays Steve Scala - Cowen David Risinger - Leerink Partners Andrew Baum - Citi Chris Schott - JPMorgan Rajesh Kumar - HSBC Michelle Rivera - inThought Research Operator Good day, everyone, and welcome to Pfizer's Second Quarter 2023 Earnings Conference Call. Today's call is being recorded. Read More
Posted: Aug 1 2023, 15:03
Author Name: Seeking Alpha
Views: 092096

PFE News  

Seeking High Dividends? 3 Fairly Valued/Undervalued High Dividend Yield Stocks For Your Portfolio

By Seeking Alpha
November 4, 2023

Seeking High Dividends? 3 Fairly Valued/Undervalued High Dividend Yield Stocks For Your Portfolio

High dividend yield companies are valuable assets for your portfolio, since they are a great way to generate added income, which you can reinvest or u more_horizontal

Should You Pick Pfizer Stock At $30?

By Forbes
November 3, 2023

Should You Pick Pfizer Stock At $30?

Pfizer (NYSE: PFE) reported its Q3 results earlier this week, with revenues missing but earnings beating the street estimates, and we believe that PFE more_horizontal

There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?

By The Motley Fool
November 3, 2023

There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?

Pfizer reported an adjusted loss of nearly $1 billion in the third quarter, and recently lowered its forecasts for coronavirus product sales. The comp more_horizontal

This High-Yield Dividend Stock Is a Proven Wealth Creator

By The Motley Fool
November 2, 2023

This High-Yield Dividend Stock Is a Proven Wealth Creator

In 2023, the broader market has ignored the deep value proposition of most large-cap pharmaceutical stocks. Pfizer, a stalwart of the industry, has be more_horizontal

UK regulator approves Pfizer's hair loss drug

By Reuters
November 1, 2023

UK regulator approves Pfizer's hair loss drug

Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease. more_horizontal

Pfizer Posted a Steep Loss. Is It Time to Sell?

By The Motley Fool
November 1, 2023

Pfizer Posted a Steep Loss. Is It Time to Sell?

Pfizer reported third-quarter results on Tuesday, Oct. 31. The company told investors it had to write down $5.6 billion worth of unused inventory in t more_horizontal

Pfizer quarterly results hit by soft demand for COVID-19 products

By Fox Business
October 31, 2023

Pfizer quarterly results hit by soft demand for COVID-19 products

Sales of the company's coronavirus vaccine Comirnaty dropped 70% during the third quarter compared with the same period a year earlier, Pfizer reporte more_horizontal

We are keen to join forces with Seagan, says Pfizer CEO Albert Bourla

By CNBC Television
October 31, 2023

We are keen to join forces with Seagan, says Pfizer CEO Albert Bourla

Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk Q3 earnings results, partnering with Kansas City Chiefs Tight End Trav more_horizontal


Search within

Pages Search Results: